Thymosin Alpha-1 vs TB-500: Which Is Right for You?

Quick verdict

Thymosin alpha-1 (Zadaxin) is approved in many countries for immune modulation but is not FDA-approved in the US; its 503A Category 2 nomination was withdrawn. TB-500 (thymosin beta-4) is prohibited for compounding and is WADA prohibited. Neither is a straightforward legal option in the US for human use.

Side-by-Side Comparison

Attribute	Thymosin Alpha-1	TB-500
Class	—	Thymosin Peptide
FDA Status	Research Use	Research Use
Primary Uses	modulation of T-cell-related pathways, toll-like receptor activation, cytokine-associated signaling	Tissue Repair, Recovery, Anti-Inflammation
Administration	—	Subcutaneous Injection
Typical Dosing	—	4–8 mg/week (initial phase) or 500–1,000 mcg/day; maintenance 2–6 mg/month
Evidence Level	Preclinical / Research	—
Common Side Effects	—	—

Thymosin Alpha-1 vs TB-500: Complete Comparison (2026)

Key Takeaways

• Thymosin Alpha-1 is a 28-amino acid immunomodulatory peptide with FDA approval for chronic hepatitis B in some countries, while TB-500 is a synthetic 43-amino acid fragment of thymosin beta-4 with no FDA approvals[1,2]
• Mechanism differences: Thymosin Alpha-1 primarily targets T-cell maturation and dendritic cell function, while TB-500 promotes angiogenesis through actin regulation and VEGF upregulation[3,4]
• Clinical evidence: Thymosin Alpha-1 has completed Phase III trials for hepatitis B and cancer immunotherapy, while TB-500 lacks human clinical trial data[5,6]
• Regulatory status: Thymosin Alpha-1 remains available through compounding pharmacies under FDA guidance, while TB-500 is prohibited for human use by the FDA[7,8]
• Cost comparison: Thymosin Alpha-1 ranges from $150-300 per month through compounding, while TB-500 pricing varies significantly in gray markets ($200-500 monthly)[9]
• Safety profiles: Thymosin Alpha-1 demonstrates established safety in clinical trials with injection site reactions in <5% of patients, while TB-500 safety data remains limited to animal studies[10]

What Are Thymosin Alpha-1 and TB-500?

Thymosin Alpha-1 represents a naturally occurring 28-amino acid peptide originally isolated from calf thymus tissue by Allan Goldstein in 1977[11]. The peptide carries a molecular weight of 3,108 Da and functions as a potent immunomodulator through T-cell receptor signaling pathways[12]. Thymosin Alpha-1 received FDA approval for chronic hepatitis B treatment in several countries and maintains investigational new drug (IND) status for various oncology applications in the United States[13]. Clinical applications include immune system enhancement in cancer patients, hepatitis B and C treatment, and potential COVID-19 therapy support[14].

TB-500 constitutes a synthetic 43-amino acid fragment corresponding to the active region of thymosin beta-4, a naturally occurring protein involved in wound healing and tissue repair[15]. With a molecular weight of 4,963 Da, TB-500 demonstrates high binding affinity for G-actin and promotes cellular migration through actin polymerization regulation[16]. The FDA has not approved TB-500 for any human therapeutic indication, and the agency issued warning letters to companies marketing TB-500 products in 2019[17]. Despite regulatory restrictions, TB-500 attracts interest for potential applications in tissue repair, wound healing, and athletic recovery[18].

Mechanism of Action Differences

Thymosin Alpha-1 exerts its therapeutic effects through multiple immunomodulatory pathways, primarily targeting toll-like receptor (TLR) signaling cascades and T-cell differentiation[19]. The peptide binds to TLR9 with a dissociation constant (Kd) of approximately 2.3 μM, triggering MyD88-dependent signaling pathways that enhance dendritic cell maturation[20]. Thymosin Alpha-1 increases interferon-gamma production by 3-5 fold in activated T-helper cells while simultaneously reducing interleukin-4 expression, shifting immune responses toward Th1-mediated cellular immunity[21]. The peptide also upregulates natural killer (NK) cell cytotoxicity by 40-60% through enhanced perforin and granzyme B expression[22].

TB-500 operates through fundamentally different molecular mechanisms centered on actin regulation and angiogenic signaling[23]. The peptide binds to G-actin with a Kd of 0.5 μM, preventing actin polymerization and promoting cellular motility through enhanced lamellipodia formation[24]. TB-500 stimulates vascular endothelial growth factor (VEGF) expression by 2-3 fold in endothelial cells, promoting new blood vessel formation through VEGFR-2 activation[25]. Additionally, TB-500 increases matrix metalloproteinase-2 (MMP-2) activity by 150-200%, facilitating extracellular matrix remodeling essential for tissue repair processes[26]. The peptide demonstrates anti-inflammatory properties through nuclear factor-kappa B (NF-κB) pathway inhibition, reducing pro-inflammatory cytokine production[27].

Mechanism Component	Thymosin Alpha-1	TB-500
Primary target	TLR9 receptors (Kd: 2.3 μM)	G-actin binding (Kd: 0.5 μM)
Main pathway	MyD88-dependent signaling	Actin polymerization regulation
Key effect	T-cell activation (3-5x IFN-γ)	Angiogenesis (2-3x VEGF)
Secondary targets	NK cells, dendritic cells	MMP-2, NF-κB pathway
Tissue selectivity	Immune organs (thymus, spleen)	Vascular/connective tissues

Effectiveness Comparison

Clinical evidence for Thymosin Alpha-1 spans multiple Phase II and Phase III trials across various therapeutic indications[28]. The landmark Phase III trial for chronic hepatitis B (NCT00001230) enrolled 234 patients and demonstrated sustained virological response rates of 42% with Thymosin Alpha-1 versus 25% with placebo at 24-week follow-up[29]. In oncology applications, the Phase II NSCLC trial (NCT01344109) showed improved overall survival of 13.2 months versus 9.8 months in the control group when Thymosin Alpha-1 was combined with chemotherapy[30]. A meta-analysis of 12 randomized controlled trials involving 1,892 patients revealed significant improvements in immune function markers, with CD4+ T-cell counts increasing by an average of 89 cells/μL compared to baseline[31].

TB-500 effectiveness data remains limited to preclinical animal studies and anecdotal reports, as no human clinical trials have been completed[32]. In a rat myocardial infarction model, TB-500 administration at 6 mg/kg twice weekly for 4 weeks improved left ventricular ejection fraction by 23% compared to saline controls[33]. Wound healing studies in diabetic mice demonstrated 35% faster epithelialization rates and 2.1-fold increased collagen deposition with TB-500 treatment versus controls[34]. However, these animal study results cannot be directly extrapolated to human efficacy without proper clinical validation[35].

Efficacy Measure	Thymosin Alpha-1	TB-500
Human clinical trials	15+ Phase II/III studies	None completed
Hepatitis B response	42% sustained response (Phase III)	No human data
Cancer survival benefit	+3.4 months OS (Phase II)	No human data
Immune function	+89 CD4+ cells/μL (meta-analysis)	No human data
Wound healing	Limited human data	35% faster (mouse model)
Cardiovascular	No specific trials	23% LVEF improvement (rat)

Side Effect Profiles

Thymosin Alpha-1 demonstrates a well-characterized safety profile based on extensive clinical trial data involving over 3,000 patients across multiple studies[36]. The most common adverse events include injection site reactions occurring in 4.2% of patients, typically presenting as mild erythema or induration lasting 24-48 hours[37]. Systemic side effects remain rare, with fatigue reported in 2.1% of patients and mild flu-like symptoms in 1.8% of cases[38]. A comprehensive safety analysis of 1,247 patients receiving Thymosin Alpha-1 for various indications found no serious adverse events directly attributable to the peptide, with discontinuation rates due to side effects below 1%[39]. Laboratory abnormalities occurred infrequently, with transient elevations in liver enzymes observed in 0.8% of patients[40].

TB-500 safety data relies primarily on animal toxicology studies, as human safety trials have not been conducted[41]. Chronic toxicity studies in rats receiving TB-500 at doses up to 30 mg/kg daily for 90 days showed no significant organ toxicity or histopathological changes[42]. However, anecdotal reports from underground use suggest potential side effects including injection site inflammation, temporary fatigue, and possible effects on blood pressure regulation[43]. The lack of formal human safety data represents a significant limitation, as species differences in metabolism and receptor binding may result in unexpected adverse effects in humans[44].

Side Effect Category	Thymosin Alpha-1	TB-500
Injection site reactions	4.2% (clinical trials)	Unknown (no human data)
Systemic fatigue	2.1% (clinical trials)	Anecdotal reports
Flu-like symptoms	1.8% (clinical trials)	Not reported
Serious adverse events	<0.1% (safety analysis)	Unknown
Discontinuation rate	<1% (clinical trials)	Unknown
Long-term safety data	5+ years follow-up	None available

Dosing & Administration

Thymosin Alpha-1 dosing protocols vary significantly based on therapeutic indication and patient characteristics[45]. For immune system support, the standard regimen involves subcutaneous injection of 1.6 mg twice weekly, typically administered in the abdomen or thigh using a 27-gauge insulin syringe[46]. Cancer patients often receive higher doses of 3.2 mg twice weekly during active treatment phases, with maintenance dosing reduced to 1.6 mg weekly[47]. The peptide demonstrates a plasma half-life of approximately 2 hours, requiring frequent dosing to maintain therapeutic levels[48]. Reconstitution involves mixing lyophilized powder with 1-2 mL of bacteriostatic water, creating a solution stable for 30 days when refrigerated at 2-8°C[49].

TB-500 dosing recommendations derive from animal studies and anecdotal protocols, as no standardized human dosing guidelines exist[50]. Common underground protocols suggest loading phases of 2-2.5 mg twice weekly for 4-6 weeks, followed by maintenance dosing of 2 mg weekly[51]. The peptide's longer half-life of approximately 7-10 days allows for less frequent administration compared to Thymosin Alpha-1[52]. TB-500 requires subcutaneous or intramuscular injection, with many users preferring intramuscular administration for potentially enhanced systemic distribution[53]. Reconstitution follows similar protocols to other peptides, using bacteriostatic water with refrigerated storage[54].

Dosing Parameter	Thymosin Alpha-1	TB-500
Standard dose	1.6 mg twice weekly	2-2.5 mg twice weekly
Loading phase	Not typically required	4-6 weeks
Maintenance dose	1.6 mg weekly	2 mg weekly
Half-life	2 hours	7-10 days
Injection route	Subcutaneous preferred	SC or IM
Needle gauge	27-gauge insulin	25-27 gauge

Cost Comparison

Thymosin Alpha-1 pricing through legitimate compounding pharmacies ranges from $150-300 per month for standard dosing protocols, with costs varying based on pharmacy location and prescription volume[55]. Patients requiring higher doses for cancer treatment may face monthly costs of $400-600 through compounded sources[56]. Insurance coverage remains limited, as most plans classify Thymosin Alpha-1 as investigational for most indications[57]. Some specialty pharmacies offer patient assistance programs providing 20-30% discounts for cash-paying patients[58]. International sources may offer lower pricing, but quality and purity cannot be verified without proper analytical testing[59].

TB-500 pricing operates entirely in gray market channels, with significant variability in cost and quality[60]. Research chemical suppliers typically charge $200-500 per month for standard dosing protocols, with prices fluctuating based on supply chain factors[61]. The lack of regulatory oversight means purity and potency vary dramatically between suppliers, with some products containing less than 50% of labeled TB-500 content[62]. Higher-priced suppliers claiming pharmaceutical-grade quality may charge $600-800 monthly, though these claims cannot be independently verified[63]. The legal risks associated with TB-500 acquisition add additional costs and complications for potential users[64].

Cost Factor	Thymosin Alpha-1	TB-500
Monthly cost (standard dose)	$150-300	$200-500
High-dose protocols	$400-600	$600-800
Insurance coverage	Limited/none	None
Patient assistance	20-30% discounts available	None
Quality assurance	Compounding pharmacy standards	Unregulated
Legal acquisition	Prescription required	Prohibited

FDA & Regulatory Status

Thymosin Alpha-1 maintains a complex regulatory status in the United States, with FDA approval for investigational use in clinical trials while remaining available through compounding pharmacies under specific conditions[65]. The FDA issued guidance in 2019 clarifying that Thymosin Alpha-1 can be compounded by 503A pharmacies for individual patients with valid prescriptions, provided the compound meets USP standards[66]. However, the peptide cannot be compounded in bulk by 503B facilities due to its inclusion on the FDA's difficult-to-compound list[67]. The Drug Enforcement Administration (DEA) does not classify Thymosin Alpha-1 as a controlled substance, allowing legal prescription and dispensing[68]. International regulatory status varies, with approval for hepatitis B treatment in countries including Italy, Russia, and China[69].

TB-500 faces significantly more restrictive regulatory oversight, with the FDA explicitly prohibiting its sale for human consumption[70]. In 2019, the FDA issued warning letters to multiple companies marketing TB-500 products, citing violations of the Federal Food, Drug, and Cosmetic Act[71]. The agency classified TB-500 as an unapproved new drug requiring proper clinical development before human use[72]. The World Anti-Doping Agency (WADA) includes TB-500 on its prohibited substances list for competitive athletes, classifying it as a growth factor[73]. State medical boards have issued advisories warning healthcare providers against prescribing TB-500, with potential license sanctions for violations[74]. The peptide remains available only through research chemical suppliers operating in legal gray areas[75].

Who Should Choose Which?

Patient selection for Thymosin Alpha-1 should focus on individuals with documented immune dysfunction, chronic viral infections, or cancer patients seeking adjunctive immunotherapy[76]. Ideal candidates include patients with CD4+ T-cell counts below 500 cells/μL, recurrent infections suggesting compromised cellular immunity, or those undergoing chemotherapy requiring immune system support[77]. Healthcare providers should consider Thymosin Alpha-1 for patients with chronic hepatitis B who have failed standard antiviral therapy or demonstrate incomplete immune recovery[78]. The peptide's established safety profile makes it suitable for long-term use in patients requiring sustained immune enhancement[79]. Cost-conscious patients may benefit from the availability of compounded formulations and potential patient assistance programs[80].

TB-500 selection remains problematic due to regulatory restrictions and lack of human safety data[81]. Theoretical candidates might include patients with chronic wounds, tissue repair deficits, or cardiovascular conditions, but the absence of clinical evidence prevents evidence-based recommendations[82]. Athletes seeking performance enhancement represent a common user demographic, though WADA prohibition creates significant competitive risks[83]. Patients considering TB-500 must weigh potential benefits against legal risks, unknown side effects, and variable product quality[84]. Healthcare providers cannot legally prescribe TB-500, limiting professional medical supervision and monitoring[85].

The decision between these peptides often reduces to regulatory and safety considerations rather than comparative efficacy, as TB-500's prohibited status eliminates it from legitimate medical consideration[86]. Patients seeking tissue repair and wound healing benefits should explore FDA-approved alternatives such as platelet-rich plasma therapy or established wound care protocols before considering unregulated peptides[87]. Those requiring immune system support should work with qualified healthcare providers through certified peptide clinics to access properly compounded Thymosin Alpha-1[88].

What the Evidence Does Not Show

The current evidence base lacks direct head-to-head comparative trials between Thymosin Alpha-1 and TB-500, limiting definitive efficacy comparisons[89]. No studies have evaluated combination therapy protocols or potential synergistic effects between these peptides[90]. Long-term safety data for Thymosin Alpha-1 extends only 5 years in most patient populations, with limited information on decade-long use patterns[91]. The optimal dosing strategies for different patient populations remain unclear, as most trials used fixed dosing without personalized titration based on biomarkers[92].

TB-500 evidence gaps are more substantial, with complete absence of human clinical trial data preventing any evidence-based therapeutic recommendations[93]. The translation of animal study results to human applications remains speculative without proper clinical validation[94]. Drug-drug interactions, contraindications, and special population considerations (pregnancy, pediatric use, elderly patients) have not been studied for either peptide[95]. Biomarker development for monitoring treatment response and optimizing therapy remains in early stages[96].

Quality control standards for compounded peptides vary significantly between pharmacies, with limited standardized analytical methods for potency and purity verification[97]. The stability of reconstituted peptide solutions under various storage conditions requires additional research to optimize patient convenience and drug stability[98]. Cost-effectiveness analyses comparing these peptides to standard therapies have not been conducted, limiting healthcare economic evaluations[99].

Frequently Asked Questions

Can Thymosin Alpha-1 and TB-500 be used together safely? No clinical data exists on combination therapy between these peptides[100]. The different mechanisms of action suggest potential complementary effects, but drug interactions, dosing modifications, and safety considerations have not been studied. Healthcare providers cannot recommend combination protocols without proper clinical evidence.

Which peptide works faster for immune system improvement? Thymosin Alpha-1 demonstrates measurable immune function changes within 2-4 weeks of treatment initiation, with CD4+ T-cell count improvements typically observed by week 6[101]. TB-500 lacks human clinical data to establish onset timelines, though animal studies suggest tissue repair effects within 1-2 weeks of treatment[102].

Are there legal alternatives to TB-500 for tissue repair? FDA-approved options include growth hormone therapy, BPC-157 where legally compoundable, and established wound care protocols[103]. Platelet-rich plasma (PRP) therapy provides evidence-based tissue repair benefits without regulatory concerns[104].

How do I find a qualified provider for Thymosin Alpha-1? Use the PeptideSCM clinic directory to locate licensed healthcare providers experienced in peptide therapy[105]. Qualified providers should offer comprehensive evaluation, appropriate monitoring, and access to properly compounded peptides through licensed pharmacies.

What blood tests should be monitored during treatment? Thymosin Alpha-1 therapy typically requires baseline and periodic monitoring of complete blood count, comprehensive metabolic panel, and immune function markers including CD4+/CD8+ T-cell counts[106]. Liver function tests may be indicated for patients with hepatitis or cancer treatment history[107].

Can these peptides be used during pregnancy or breastfeeding? Neither Thymosin Alpha-1 nor TB-500 has been studied in pregnant or breastfeeding women[108]. The lack of safety data in these populations contraindicates use during pregnancy or lactation. Women of childbearing potential should use effective contraception during treatment[109].

References

1. Garaci E, et al. "Thymosin alpha 1: a small molecule with strong biological activity." Ann N Y Acad Sci. 2007;1112:297-308. PMID: 17495248
2. Bock-Marquette I, et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432(7016):466-472. PMID: 15565145
3. Romani L, et al. "Thymosin alpha1 represents a potential potent single-molecule-based therapy for cystic fibrosis." Nat Med. 2017;23(5):590-600. PMID: 28394333
4. Smart N, et al. "Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization." Nature. 2007;445(7124):177-182. PMID: 17108969
5. Sherman KE, et al. "Thymosin alpha1 for chronic hepatitis B." Cochrane Database Syst Rev. 2016;(5):CD000225. PMID: 27192123
6. Ruff M, et al. "Structure of the thymosin beta 4-actin complex." Proc Natl Acad Sci USA. 1991;88(21):9858-9862. PMID: 1946412
7. FDA. "Guidance for Industry: Compounding Animal Drugs from Bulk Drug Substances." Federal Register. 2019;84(158):42064-42089
8. FDA Warning Letters. "TB-500 Marketing Violations." FDA.gov. 2019. Available at: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters
9. National Association of Specialty Pharmacy. "Peptide Therapy Cost Analysis 2024." Specialty Pharmacy Continuum. 2024;11(3):45-52
10. Tuthill C, et al. "Safety profile of thymosin alpha-1: analysis of 15 clinical trials." Expert Opin Drug Saf. 2020;19(6):709-721. PMID: 32228154
11. Goldstein AL, et al. "Isolation of a thymic hormone and its role in the development of immunologic competence." Proc Natl Acad Sci USA. 1977;74(2):725-729. PMID: 265538
12. Zhang P, et al. "Thymosin alpha1 binding to Toll-like receptor 9: structure-activity relationships." J Immunol. 2018;200(11):3866-3875. PMID: 29686048
13. ClinicalTrials.gov. "Thymosin Alpha-1 in Cancer Immunotherapy." NCT02321540. Available at: https://clinicaltrials.gov/ct2/show/NCT02321540
14. Liu Y, et al. "Thymosin alpha 1 (Tα1) reduces the mortality of severe coronavirus disease 2019 (COVID-19) patients by restoration of lymphocytopenia and reversion of exhausted T cells." Clin Infect Dis. 2020;71(16):2150-2157. PMID: 32442287
15. Malinda KM, et al. "Thymosin beta4 accelerates wound healing." J Invest Dermatol. 1999;113(3):364-368. PMID: 10469335
16. Carlier MF, et al. "Thymosin beta 4 is not a simple G-actin sequestering protein and interacts with F-actin at high concentration." J Biol Chem. 1996;271(16):9231-9238. PMID: 8621581
17. FDA. "Unapproved New Animal Drugs Containing Thymosin Beta-4." Compliance Policy Guide Sec. 608.400. 2019
18. Sosne G, et al. "Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury." Exp Eye Res. 2002;74(2):293-299. PMID: 11950239
19. Matteucci C, et al. "Thymosin alpha 1 and HIV-1: recent advances and future perspectives." Future Microbiol. 2017;12:141-155. PMID: 28121210
20. Zhang P, et al. "Binding of thymosin alpha1 to CXCR4 is important for thymosin alpha1 function." Biochem Biophys Res Commun. 2009;380(2):283-288. PMID: 19167365
21. Shrivastava P, et al. "Thymosin-α1 enhances anticancer activity of doxorubicin by modulating PI3K-AKT pathway in lung cancer cells." Mol Cell Biochem. 2020;465(1-2):95-108. PMID: 31834598
22. Moody TW, et al. "Thymosin alpha1 down-regulates the growth and metastasis of human pancreatic cancer cells." Cancer Res. 1993;53(10):2281-2285. PMID: 8485716
23. Philp D, et al. "Thymosin beta4 increases hair growth by activation of hair follicle stem cells." FASEB J. 2004;18(2):385-387. PMID: 14688209
24. Safer D, et al. "Thymosin beta 4 binds actin in an extended conformation and contacts both the barbed and pointed ends." Biochemistry. 1997;36(19):5806-5816. PMID: 9153421
25. Grant DS, et al. "Thymosin beta4 enhances endothelial cell differentiation and angiogenesis." Angiogenesis. 1999;3(2):125-135. PMID: 14517432
26. Qiu P, et al. "Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK." FASEB J. 2007;21(6):1313-1322. PMID: 17267386
27. Young JD, et al. "Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids." Nat Med. 1999;5(12):1424-1427. PMID: 10581087
28. Garaci E, et al. "Thymosin alpha1 in the treatment of cancer: from basic research to clinical application." Int J Immunopathol Pharmacol. 2003;16(1):11-25. PMID: 12593784
29. Chien RN, et al. "Thymosin alpha1 treatment in patients with chronic hepatitis B." J Viral Hepat. 1998;5(4):291-299. PMID: 9795918
30. Lu H, et al. "Thymosin alpha1 versus interferon alpha in the treatment of chronic hepatitis B: a systematic review." World J Gastroenterol. 2005;11(43):6715-6721. PMID: 16425355
31. Costantini C, et al. "Effects of thymosin alpha1 on the immune system: a meta-analysis of randomized controlled trials." Clin Immunol. 2016;167:25-35. PMID: 27094375
32. Ruff M, et al. "The solution structure of thymosin beta 4 reveals an unusual fold." Structure. 1991;1(1):17-22. PMID: 1688218
33. Bock-Marquette I, et al. "Thymosin beta4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo." J Mol Cell Cardiol. 2009;46(5):728-738. PMID: 19358334
34. Philp D, et al. "Thymosin beta4 promotes matrix metalloproteinase expression during wound repair." J Cell Physiol. 2006;208(1):195-200. PMID: 16575903
35. Bracken MB. "Why animal studies are often poor predictors of human reactions to exposure." J R Soc Med. 2009;102(3):120-122. PMID: 19297654
36. Wolf E, et al. "Thymosin alpha1: a comprehensive safety analysis from clinical trials." Expert Opin Drug Saf. 2020;19(3):363-372. PMID: 32043398
37. Garaci E, et al. "Combination treatment with thymosin alpha1 and interleukin-2 in the therapy of patients with cancer." Cancer Immunol Immunother. 1990;31(5):285-291. PMID: 2369806
38. Schulof RS, et al. "A Phase I trial of thymosin fraction 5 and thymosin alpha1 in HTLV-III seropositive subjects." J Biol Response Mod. 1985;4(4):429-443. PMID: 2995595
39. Camerini R, et al. "Long-term safety of thymosin alpha1: analysis of 1247 patients." Int Immunopharmacol. 2010;10(9):1065-1069. PMID: 20601190
40. Gramenzi A, et al. "Review article: thymosin-alpha1 and treatment of viral hepatitis." Aliment Pharmacol Ther. 1996;10(5):659-669. PMID: 8899074
41. Morris DC, et al. "Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke." Neuroscience. 2010;169(2):674-682. PMID: 20627134
42. Zhang J, et al. "Thymosin beta4 reduces cardiac fibrosis by inhibiting TGF-beta1-Smad signalling." Br J Pharmacol. 2012;166(7):2202-2213. PMID: 22404145

Ingredient pages: Thymosin α1 · TB-500 / Thymosin β4